Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1...
-
Evaluation of strategic alternatives ongoing BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results. In September 2019,...
-
BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
-
Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study...
-
BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
-
Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the...
-
BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
-
Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data...
-
Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression...
-
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company is currently in the formal regulatory process related to the clinical hold for...